ABSTRACT
OBJECTIVES: To optimize 68Ga production using a liquid cyclotron target, investigations were performed to compare production yields using different concentrations of [68Zn]Zn(NO3)2, nitric acid, and irradiation parameters. METHODS: Different concentrations of [68Zn]Zn(NO3)2 (0.6â¯M, 1.2â¯M and 1.42â¯M) in varying normality of nitric acid (0.8-1.5â¯N) were prepared and irradiated with protons (incident energy ~14â¯MeV) using a BMLT-2 liquid target at different beam currents (30-50⯵A) and irradiation times (30-60â¯min). The 68Ga production and saturation yields were calculated and compared. [68Ga]GaCl3 was isolated using in-house developed hydroxamate resin and optimized for routine application. Recycling of [68Zn]Zn(NO3)2 from the recovered target solution was also investigated. RESULTS: On increasing concentration of [68Zn]Zn(NO3)2 from 0.6â¯M to 1.2â¯M in 0.8â¯N nitric acid, decay corrected yield of 68Ga at EOB was found to be 1.64â¯GBq (44.4â¯mCi) and 3.37â¯GBq (91.0â¯mCi), respectively at 30⯵A beam current, indicating production yield was proportional to zinc nitrate concentration for a 30â¯min irradiation. However, when beam current was increased to 40⯵A while maintaining nitric acid concentration at 0.8â¯N, the proportional relationship of 68Zn-concentration with 68Ga production yield was lost [0.6â¯M, 2.29â¯GBq (61.9â¯mCi); 1.2â¯M, 3.6â¯GBq (97.3â¯mCi)] for a 30â¯min irradiation. In fact, the effect was more profound for 60â¯min irradiations [0.6â¯M, 2.96â¯GBq (80.0â¯mCi); 1.2â¯M, 4.25â¯GBq (115â¯mCi)]. Increasing nitric acid concentration to 1.25-1.5â¯N improved 68Ga production yield for 40⯵A, 60-min irradiations (1.2â¯M; 5.17â¯GBq (140â¯mCi)). MP-AES analysis showed metal impurities as <0.20⯵gâ¯Ga (nâ¯=â¯3), <0.93⯵g Zn (nâ¯=â¯3) andâ¯<â¯2.7⯵g Fe (nâ¯=â¯3). Based on above finding, 1.42â¯M [68Zn]Zn(NO3)2 in 1.2â¯N-HNO3 solutions were also studied to achieve highest production yields of 9.85⯱â¯2.09â¯GBq (266⯱â¯57â¯mCi) for 60â¯min irradiation at 40⯵A beam current. After recycling,> 99% pure recycled [68Zn]zinc nitrate was obtained in 82.6⯱â¯13.6% yield. CONCLUSIONS: 68Ga production yields were dependent on all four variables: concentrations of [68Zn]Zn(NO3)2 and nitric acid, beam current and duration of irradiation. Of note, increasing beam current and irradiation time may require increased concentrations of nitric acid to achieve expected increments in 68Ga production yield.
Subject(s)
Cyclotrons/instrumentation , Gallium Radioisotopes/metabolism , Nitrates/chemistry , Radiochemistry , Radiopharmaceuticals/metabolism , Zinc Compounds/chemistry , Gallium/chemistry , Gallium Radioisotopes/chemistry , Gallium Radioisotopes/isolation & purification , Humans , Hydroxamic Acids/chemistry , Isotope Labeling/methods , Positron-Emission Tomography , Protons , Radiopharmaceuticals/isolation & purificationABSTRACT
The five melanocortin receptors (MC1R-MC5R) are involved in numerous biological pathways, including steroidogenesis, pigmentation, and food intake. In particular, MC3R and MC4R knockout mice suggest that the MC3R and MC4R regulate energy homeostasis in a non-redundant manner. While MC4R-selective agonists have been utilized as appetite modulating agents, the lack of MC3R-selective agonists has impeded progress in modulating this receptor in vivo. In this study, the (pI)DPhe position of the tetrapeptide Ac-His-Arg-(pI)DPhe-Tic-NH2 (an MC3R agonist/MC4R antagonist ligand) was investigated with a library of 12 compounds. The compounds in this library were found to have higher agonist efficacy and potency at the mouse (m) MC3R compared to the MC4R, indicating that the Arg-DPhe motif preferentially activates the mMC3R over the mMC4R. This observation may be used in the design of new MC3R-selective ligands, leading to novel probe and therapeutic lead compounds that will be useful for treating metabolic disorders.
Subject(s)
Oligopeptides , Receptors, Melanocortin/agonists , Animals , HEK293 Cells , Humans , Mice , Mice, Knockout , Oligopeptides/chemical synthesis , Oligopeptides/chemistry , Oligopeptides/pharmacology , Receptors, Melanocortin/genetics , Receptors, Melanocortin/metabolism , Structure-Activity RelationshipABSTRACT
The discovery of the endogenous melanocortin agonists in the 1950s have resulted in sixty years of melanocortin ligand research. Early efforts involved truncations or select modifications of the naturally occurring agonists leading to the development of many potent and selective ligands. With the identification and cloning of the five known melanocortin receptors, many ligands were improved upon through bench-top in vitro assays. Optimization of select properties resulted in ligands adopted as clinical candidates. A summary of every melanocortin ligand is outside the scope of this review. Instead, this review will focus on the following topics: classic melanocortin ligands, selective ligands, small molecule (non-peptide) ligands, ligands with sex-specific effects, bivalent and multivalent ligands, and ligands advanced to clinical trials. Each topic area will be summarized with current references to update the melanocortin field on recent progress. This article is part of a Special Issue entitled: Melanocortin Receptors - edited by Ya-Xiong Tao.
Subject(s)
Drug Discovery/methods , Melanocortins/chemistry , Melanocortins/pharmacology , Receptors, Melanocortin/metabolism , Small Molecule Libraries/chemistry , Small Molecule Libraries/pharmacology , Amino Acid Sequence , Animals , Humans , Ligands , Models, Molecular , Receptors, Melanocortin/agonists , Receptors, Melanocortin/antagonists & inhibitors , Receptors, Melanocortin/chemistryABSTRACT
Aldehyde dehydrogenases (ALDHs) catalyze the NAD(P)+-dependent oxidation of aldehydes to carboxylic acids and are important for metabolism and detoxification. Although the ALDH superfamily fold is well established, some ALDHs contain an uncharacterized domain of unknown function (DUF) near the C terminus of the polypeptide chain. Herein, we report the first structure of a protein containing the ALDH superfamily DUF. Proline utilization A from Sinorhizobium meliloti (SmPutA) is a 1233-residue bifunctional enzyme that contains the DUF in addition to proline dehydrogenase and l-glutamate-γ-semialdehyde dehydrogenase catalytic modules. Structures of SmPutA with a proline analog bound to the proline dehydrogenase site and NAD+ bound to the ALDH site were determined in two space groups at 1.7-1.9 Å resolution. The DUF consists of a Rossmann dinucleotide-binding fold fused to a three-stranded ß-flap. The Rossmann domain resembles the classic ALDH superfamily NAD+-binding domain, whereas the flap is strikingly similar to the ALDH superfamily dimerization domain. Paradoxically, neither structural element performs its implied function. Electron density maps show that NAD+ does not bind to the DUF Rossmann fold, and small-angle X-ray scattering reveals a novel dimer that has never been seen in the ALDH superfamily. The structure suggests that the DUF is an adapter domain that stabilizes the aldehyde substrate binding loop and seals the substrate-channeling tunnel via tertiary structural interactions that mimic the quaternary structural interactions found in non-DUF PutAs. Kinetic data for SmPutA indicate a substrate-channeling mechanism, in agreement with previous studies of other PutAs.